Immune checkpoints: A therapeutic target in triple negative breast cancer

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Chawla, Akhil ^a   Philips, Anne V ^a   Alatrash, Gheath ^a   Mittendorf, Elizabeth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; Immunotherapy; PD L1; PI3K; Triple negative breast cancer

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AMP 514; AMP 541; ANTINEOPLASTIC AGENT; BMS 936559; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RAPAMYCIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IMMUNE CHECKPOINT; IMMUNE RESPONSE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SOLID TUMOR; STOMACH CANCER; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84902590227     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28325     Document Type: Note

References (10)

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; http://dx.doi.org/10.1126/science.342.6165.1432
2. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-65; PMID:7543139; http://dx.doi.org/10.1084/jem.182.2.459
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
4. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11:3887-95; PMID:1396582
5. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
7. Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park J, Kollia G, Taube JM, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013 (Supplement); 31:3016
8. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington SM, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. PD-L1 Expression in Triple Negative Breast Cancer. Cancer Immunol Res 2014; (Forthcoming); http://dx.doi.org/10.1158/2326-6066.CIR-13-0127
9. Vreeland TJ, Clifton G, Hale DF, Sears AK, Patil R, Holmes JP, Ponniah S, Mittendorf EA, Peoples GE. Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine. Cancer Res 2012 (Supplement 3); 72:P5-16-02
10. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm1100